| Sep 30 |
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
|
| Sep 30 |
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
|
| Sep 25 |
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
|
| Sep 24 |
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
|
| Sep 18 |
CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances
|
| Sep 17 |
Mark Cuban Foundation and CSL Bring Free AI Bootcamp to Philadelphia Teens
|
| Sep 17 |
CSL Joins Accumulus Synergy to Drive Industry Change
|
| Sep 13 |
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
|
| Sep 5 |
CSL (ASX:CSL) Ticks All The Boxes When It Comes To Earnings Growth
|
| Aug 29 |
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
|
